Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Jason Marcotte who wrote (272)	6/10/1998 12:34:00 AM
From: Garry K.	Respond to of 572

Jason, I agree Jason, I feel this is a tremendous buying opportunity. The fundamentals of the company are getting ever stronger. What perplexes me, is the lack of market interest. I have addressed this concern to Laurie at IR, and if I get any insight, I will share it with the thread. Xillix today also appointed a new chairman. Here is the release.... lix Technologies: Gibbons Appointed Xillix Chairman RICHMOND, BRITISH COLUMBIA--The Board of Directors of Xillix Technologies Corp. has elected Mr. Richard P. Gibbons to the position of Chairman. Mr. Gibbons, a lawyer and businessman, is replacing Mr. Winslow W. Bennett, who resigned, as Chairman, after having held that position for the past seven years. Mr. Bennett will continue as a director of Xillix. "I am pleased to take on this responsibility at a key time for Xillix. I would like to thank Mr. Bennett for his years of guidance and support." said Mr. Gibbons "With the recent joint venture announced with Miravant, who is developing photodynamic drugs to treat cancer, Xillix is now in a healthy cash position, and has added to its future earning potential through device sales and a drug royalty. Xillix will remain on track with its own device development and sales of Xillix LIFE-Lung and Xillix LIFE-GI while looking forwards to the potential created by its new involvement with Miravant." Mr. Gibbons received his law degree, from the University of British Columbia, in 1967. Following that he practiced corporate, securities and civil litigation law. Mr. Gibbons is currently President of Osler Developments Ltd. Mr. Gibbons is one of the original investors in Xillix and has been on the board for the past seven years. He is a director of several other corporations and has served on many community and non-profit boards. At Xillix's recent Annual General Meeting the following, in addition to Mr. Gibbons, were elected to the Board of Directors: Mr. Franklin D. Brown, President, FDB Healthcare Consulting; Joseph F. Damico, President and COO, Allegiance Healthcare Corp.; Jack McGinley, Group Vice President, Baxter International Inc.; Winslow W. Bennett, President, Winwood Holdings Ltd.; Michael E. Phillips, Vice President, Working Opportunity Fund Ltd.; Pierre J. Leduc, President and CEO, Xillix Technologies Corp. Xillix Technologies is a leader in the development and commercialization of proprietary medical imaging technology which helps physicians diagnose early-stage cancer. When tissue containing abnormal cells is exposed to light from Xillix's fluorescence imaging devices, physicians are able to detect pre-cancerous and cancerous cells. The Company's lead product, called the Xillix LIFE-Lung Fluorescence Endoscopy System has been approved for sale in the U.S., Canada, Europe and Japan. Worldwide marketing has been granted to Olympus Optical Co. Ltd. of Tokyo, the international endoscopy market leader. The Company is listed on the Toronto Stock Exchange under the trading symbol "XLX". Garry